PSTX - Surface Oncology Mustang Bio among top picks as BTIG turns bullish on cell and gene therapy space

“We are bullish on the cell and gene therapy space,” noted BTIG analyst Justin Zelin highlighting the importance of stock picking in the area given “the limited targets and indications to market.”In the area of cell therapy, Zelin initiates the coverage on six companies which according to the analyst “provide short-term value recognition and long-term growth potential to be disruptive players amongst the crowded landscape.”The initial recognition of CAR-T cell therapies is “profound,” argues the analyst. Zelin also points to the efforts by new entrants to advance existing treatments with more effective and lasting responses, better safety profiles, and differentiated targets.Mustang Bio ([[MBIO]] +9.4%), Surface Oncology ([[SURF]] +8.2%), Adicet Bio ([[ACET]] +6.4%), CASI Pharmaceuticals ([[CASI]] +8.0%), Legend Biotech ([[LEGN]] +13.3%), and Poseida Therapeutics ([[PSTX]] +6.8%) have all received buy ratings.The price targets of $11.00, $17.00, $34.00, $4.00, $55.00, and $40.00 implies premia ranging from ~284.6%, ~100.9%, ~158.0%, ~177.8%, ~78.0% and

For further details see:

Surface Oncology, Mustang Bio among top picks as BTIG turns bullish on cell and gene therapy space